Business Wire

FYDE

4.11.2019 12:02:08 CET | Business Wire | Press release

Share
Secure Access is Broken. Fyde Enterprise Fixes It.

Fyde, the new standard for Zero Trust, today announced Fyde Enterprise, a continuous, adaptive secure access solution that mitigates risk while protecting privacy and increasing performance. As digital transformation and the cloud transform the way we work and access apps, the disappearance of the traditional corporate perimeter creates new security risks and compliance challenges that break traditional solutions like VPNs. A powerful alternative to VPNs, Fyde Enterprise works on any infrastructure, any device, and with any application on a corporate network. Distributed businesses can now modernize remote access, enforce global security and access policies, and achieve seamless connectivity without compromising productivity.

Fyde, a first-time participant at Web Summit, is a featured startup and will be speaking on Centre Stage at the Breakout startups on November 4 at 5:00 pm and November 6 at 9:15 am. Fyde is also an exhibitor in the Beta Startup Programme on Tuesday, November 5.

Zero Trust for the Modern Enterprise

The Zero Trust paradigm assumes that all access is conditional and the network is always untrusted. Every interaction with the corporate network or cloud infrastructure must be granted contextual and conditional access based on continuous evaluation of device attributes (such as critical updates, security configuration and geographic location) and user identity (such as enforcing MFA or re-authentication) to ensure the highest levels of security.

Security teams must adapt to new requirements for the cloud, employee mobile devices, and evolving access dynamics associated with contractors, partners and remote employees. Fyde’s Zero Trust approach to secure access is driven by identity-aware access control and device-trust based security policies. Fyde enables secure, reliable and fast access to authorized apps and workloads on corporate networks and cloud infrastructure from any device, network, and location. Fyde also protects user identities from account takeover attacks.

“CISOs are frustrated by the failure of their traditional secure access solutions to deliver essential visibility and control over access to corporate resources, as well as to block emerging threats,” said Sinan Eren, Fyde CEO. “Fyde is built to address the security challenges created by the evolving threat landscape, while protecting employee privacy, boosting productivity, and ensuring compliance.”

Fyde Enterprise: The Onramp to Zero Trust

Fyde Enterprise is easy to deploy, monitor and manage. Security and IAM teams can sync with their user directory for seamless onboarding and deprovisioning of users and devices, monitor and log access requests and sessions via the Fyde Enterprise management console. Fyde Enterprise includes features for today’s complex IT environments, enabling security teams to deliver:

Zero Trust on any infrastructure or platform

  • Grant minimal privileged access to authorized apps without exposing the network
  • Work on Mobile or Desktop
  • Deploy on-premises or in hybrid or public cloud
  • Continuously verify users and devices

Global Security and Access Policies

  • Create robust access policies and gain visibility into who has access, to what and from where
  • Assign role-based and attribute-based policies

Upgraded performance and privacy

  • Eliminate latency via local inspection
  • Offer self-service remediation
  • Reduce IT Costs
  • Secure the data plane: Fyde does not have visibility into data.
  • Protect employee privacy. No personal data is shared with the company.

Pricing and availability

Fyde Enterprise is available today. Fyde is sold as an annual subscription with pricing starting at $10 per user per month. Enterprise bundles are available. To try Fyde today, visit Fyde.com/sign-up

About Fyde

Fyde is the new standard for Zero Trust secure access. An increasingly decentralized world is driving digital transformation and challenging the status quo. Fyde helps organizations mitigate risks while adapting to the new nature of work and IT, powering their journey to the Zero Trust Architecture. Our innovative approach is driven by patented technology that enables secure, reliable and fast access to any on-premises, cloud or hybrid app or workload. Fyde eliminates security risks associated with traditional VPN access, while protecting user identities from account takeover attacks. To learn more about Fyde, visit Fyde.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Visa, BILL and Billtrust Launch First Live Pilot for Trusted AI Agent Payments Between Buyer and Supplier Platforms20.10.2026 14:00:00 CEST | Press release

Demonstrates how trusted AI agents are moving beyond automation to act on behalf of buyers and suppliers in real-world commercial transactions. Visa (NYSE: V), BILL (NYSE: BILL) and Billtrust today announced they have launched the first live pilot to enable trusted AI agents to initiate and complete approved buyer invoice payments end-to-end through supplier portals. Until now, many payment portals relied on human authentication requirements that limited how approved payments could be automated. Together, with leading accounts payable and receivable solutions providers BILL and Billtrust, the Visa Intelligent CommerceTM portfolio helps bridge that gap. Leveraging offerings such as Visa Trusted Agent Protocol, AI agents can now be securely authenticated to credentialed portals. As a result, buyer payments that previously relied on manual entry can be completed by trusted AI agents, while preserving supplier control and oversight. How trusted AI agents are overcoming one of payment autom

Parse Biosciences Launches Evercode MAX, Enabling Researchers to Profile More Cells and Samples with Greater Flexibility20.10.2026 14:00:00 CEST | Press release

New modular platform gives researchers greater control over sample and cell throughput while optimizing value Parse Biosciences, the leading provider of scalable and accessible single cell sequencing and a QIAGEN company, today announced that Evercode™ MAX, a modular configuration of its flagship Evercode single cell sequencing platform, is now shipping to customers. Using the same instrument-free workflow, researchers can profile up to 2.5 times as many cells across up to twice as many samples within their existing budget, or run the same experiment at roughly half the overall cost. Evercode MAX enables researchers to build a kit configuration around their experiment, with sample barcoding and library preparation as independent kits. Evercode MAX is available for Whole Transcriptome, WT FFPE, TCR, BCR, and CRISPR Detect. With configurations supporting up to 384 samples and 2 million cells, researchers can prioritize more samples to characterize biological variation or more cells per s

Hologic and Inpeco Announce Co-Marketing Partnership to Advance Molecular Laboratory Automation20.10.2026 14:00:00 CEST | Press release

Hologic, Inc., a global leader in women’s health and diagnostics, and Inpeco S.A., the global leader in Total Laboratory Automation, today announced they have signed a co-marketing partnership for Inpeco’s automation solution FlexLab™ X and Hologic’s Panther® System in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020837126/en/ Hologic and Inpeco S.A. announce a co-marketing partnership for Inpeco's automation solution FlexLab™ X and Hologic’s Panther® System in Europe. Inpeco’s recently launched FlexLab X system enables laboratories to connect multiple Panther Systems. By combining Hologic’s fully-automated molecular diagnostics platform with FlexLab X‘s open automation capabilities, laboratories can achieve high-throughput workflows with the potential to increase sample volumes1 and enhance end-to-end sample traceability2, supporting reliable test results for optimal patient outcomes.3 The Panther System will i

FiRa Consortium Launches Core 4.1 Specifications and Enhanced Certification Program20.10.2026 14:00:00 CEST | Press release

FiRa Core 4.1 expands secure, private, and interoperable FiRa deployments. The FiRa® Consortium today announced the release of the FiRa Core 4.1 Specifications and an updated 4.1 Certification Program to help advance ultra-wideband (UWB) interoperability within the FiRa ecosystem. Core 4.1 introduces enhancements for FiRa Untracked Navigation, expanded cryptographic security certification, and additional support for concurrent ranging and data capabilities across multi-vendor FiRa deployments. The release supports deployment requirements defined by the FiRa Frameworks and Profiles Sub-Group (FPSG), including high-density indoor positioning, hardware-level security, and concurrent data capabilities for FiRa use cases. Features of the FiRa Core 4.1 Specifications and Certification ProgramEnhanced Downlink Time Difference of Arrival (DL-TDoA) for FiRa Untracked Navigation — Adds coordinate-system and anchor-location encoding options, including floor identification without increasing messa

Debiopharm Highlights Clinical Momentum Across DDR Portfolio at ESMO 2026, Advancing WEE1-Based Therapies in Ovarian and Uterine Cancers and Glioblastoma20.10.2026 14:00:00 CEST | Press release

Emerging data highlight encouraging clinical activity of zedoresertib in difficult-to-treat solid tumors, including glioblastoma, provide evidence of brain penetration, and further validate the therapeutic potential of dual WEE1/PKMYT1 inhibition in biomarker-selected populations Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced their upcoming Phase 1/Phase 2 clinical updates at the European Society for Medical Oncology (ESMO) Congress (Madrid, Spain, 23-27 October). During the event, Debiopharm will highlight clinical updates on its pipeline targeting the DNA Damage Response (DDR), featuring single-agent data on zedoresertib (Debio 0123) as well as rational combination strategies, with both temozolomide in glioblastoma and with lunresertib (Debio2513) in solid tumors. Debiopharm’s planned activities at ESMO 2026 include: Rapid Oral Presentatio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye